2024

Maldonado, H. et al. (2024) A trafficking regulatory subnetwork governs α V β 6 integrin-HER2 cross-talk to control breast cancer invasion and drug resistance. Science Advances, 10(49), eadk9944. (doi: 10.1126/sciadv.adk9944) (PMID:39630893) (PMCID:39630893)

Hanna, D. et al. (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130(12), pp. 1916-1920. (doi: 10.1038/s41416-024-02685-9) (PMID:38658782) (PMCID:PMC11183215)

Agnew, S., Crawford, M., MacPherson, I. , Shiramizu, V. and Fleming, L. (2024) The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer. Breast, 75, 103731. (doi: 10.1016/j.breast.2024.103731) (PMID:38599048) (PMCID:PMC11017041)

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

Kingston, B. et al. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14(2), pp. 274-289. (doi: 10.1158/2159-8290.CD-22-1387) (PMID:37982575) (PMCID:PMC10850945)

2023

Coakley, M. et al. (2023) Comparison of circulating tumor DNA assays for Molecular Residual Disease detection in early-stage triple negative breast cancer. Clinical Cancer Research, (doi: 10.1158/1078-0432.CCR-23-2326) (Early Online Publication)

Ring, A. et al. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29(23), pp. 4751-4759. (doi: 10.1158/1078-0432.CCR-23-1696) (PMID:37773077) (PMCID:PMC10690092)

Henriksen, P. A. et al. (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial. Circulation, 148(21), pp. 1680-1690. (doi: 10.1161/CIRCULATIONAHA.123.064274) (PMID:37746692) (PMCID:PMC10655910)

Palmieri, C. et al. (2023) A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program. British Journal of Cancer, 129(5), pp. 852-860. (doi: 10.1038/s41416-023-02352-5) (PMID:37468569)

Turner, N. C. et al. (2023) Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer. Annals of Oncology, 34(2), pp. 200-211. (doi: 10.1016/j.annonc.2022.11.005) (PMID:36423745)

2022

Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D. and MacPherson, I. (2022) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a quantitative systematic review. Breast, 64, pp. 63-84. (doi: 10.1016/j.breast.2022.04.010)

Winter, M. et al. (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35, 100442. (doi: 10.1016/j.jbo.2022.100442)

Morrison, A., Marshall-Mckenna, R. , McFadyen, A. K., Hutchison, C., Rice, A.-M., Stirling, L., McIlroy, P. and MacPherson, I. R. (2022) A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer. Scientific Reports, 12, 11575. (doi: 10.1038/s41598-022-13327-6) (PMID:35798751) (PMCID:PMC9262963)

Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)

Coombes, R.C. et al. (2022) Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nature Communications, 13, 3246. (doi: 10.1038/s41467-022-30666-0) (PMID:35688802) (PMCID:PMC9187670)

Razis, E. et al. (2022) Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. ESMO Open, 7(3), 100483. (doi: 10.1016/j.esmoop.2022.100483) (PMID:35576695) (PMCID:PMC9291630)

Malorni, L. et al. (2022) Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 164, pp. 39-51. (doi: 10.1016/j.ejca.2021.12.030) (PMID:35172272)

2021

Rabas, N. et al. (2021) PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. Journal of Cell Biology, 220(12), e202006049. (doi: 10.1083/jcb.202006049) (PMID:34623384) (PMCID:PMC8641410)

Gray, E., Figueroa, J.D., Oikonomidou, O., MacPherson, I. , Urquhart, G., Cameron, D.A. and Hall, P.S. (2021) Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open, 6(6), 100331. (doi: 10.1016/j.esmoop.2021.100331) (PMID:34864502) (PMCID:PMC8649669)

Turner, N. C. et al. (2021) Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study. Clinical Cancer Research, 27(20), pp. 5482-5491. (doi: 10.1158/1078-0432.CCR-21-0310) (PMID:34301749) (PMCID:PMC8530899)

Peddie, N., Agnew, S., Crawford, M., Dixon, D., MacPherson, I. and Fleming, L. (2021) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a qualitative systematic review and thematic synthesis. Breast, 58, pp. 147-159. (doi: 10.1016/j.breast.2021.05.005) (PMID:34049260) (PMCID:PMC8165559)

Palmieri, C. and MacPherson, I. R. (2021) A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients with cancer and liver impairment. ESMO Open, 6(3), 100162. (doi: 10.1016/j.esmoop.2021.100162)

Kingston, B. et al. (2021) Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 12, 2423. (doi: 10.1038/s41467-021-22605-2) (PMID:33893289) (PMCID:PMC8065112)

Macpherson, I. R. , He, Y. and Palmieri, C. (2021) Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305. Breast Cancer Research, 23, 33. (doi: 10.1186/s13058-021-01407-w) (PMID:33736675) (PMCID:PMC7977154)

Earl, H.M. et al. (2021) Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33(1), pp. 15-19. (doi: 10.1016/j.clon.2020.07.006) (PMID:32723485) (PMCID:PMC7382576)

Pascual, J. et al. (2021) Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers. Cancer Discovery, 11(1), pp. 92-107. (doi: 10.1158/2159-8290.CD-20-0553) (PMID:32958578)

2020

Turner, N. C. et al. (2020) Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncology, 21(10), pp. 1296-1308. (doi: 10.1016/S1470-2045(20)30444-7) (PMID:32919527) (PMCID:PMC7599319)

Conefrey, C. et al. (2020) Strategies to improve recruitment to a de-escalation trial: a mixed-methods study of the OPTIMA prelim trial in early breast cancer. Clinical Oncology, 32(6), pp. 382-389. (doi: 10.1016/j.clon.2020.01.029) (PMID:32089356) (PMCID:PMC7246331)

Tzolos, E. et al. (2020) Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy. Clinical Oncology, 32(5), pp. 292-297. (doi: 10.1016/j.clon.2019.11.008) (PMID:31813662) (PMCID:PMC7139216)

Coleman, R. et al. (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials, 21, 89. (doi: 10.1186/s13063-019-3643-6) (PMID:31941523) (PMCID:PMC6961242)

2019

MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)

Banerji, U. et al. (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, 20(8), pp. 1124-1135. (doi: 10.1016/S1470-2045(19)30328-6) (PMID:31257177)

Palmieri, C. and Macpherson, I. (2019) Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution. Lancet Oncology, 20(6), e289. (doi: 10.1016/S1470-2045(19)30296-7) (PMID:31162096)

2018

Copson, E. et al. (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: data from a multi-centre retrospective review. Breast, 42, pp. 133-141. (doi: 10.1016/j.breast.2018.09.003) (PMID:30278369)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, 5069. (doi: 10.1038/s41467-018-07339-y) (PMID:30498210) (PMCID:PMC6265295)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi: 10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) The NTOX-G12- A New Clinical Assessment Tool for Nail Problems as a Result of Taxane Chemotherapy Regimens. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) Taxane Chemotherapy and Nail Toxicity in Women with Breast Cancer: An Evaluation of Interventions. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

2017

Dornier, E. et al. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8, 2255. (doi: 10.1038/s41467-017-02101-2) (PMID:29269878) (PMCID:PMC5740148)

Hall, P. S. et al. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20(10), pp. 1311-1318. (doi: 10.1016/j.jval.2017.04.021) (PMID:29241890)

Cain, H., MacPherson, I.R. , Beresford, M., Pinder, S.E., Pong, J. and Dixon, J.M. (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clinical Oncology, 29(10), pp. 642-652. (doi: 10.1016/j.clon.2017.06.003) (PMID:28669449)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi: 10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I. , Edwards, J. , Zanivan, S. and Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130(4), pp. 697-711. (doi: 10.1242/jcs.190835) (PMID:28062852)

2016

Kristeleit, H., Parton, M., Beresford, M., Macpherson, I. R. , Sharma, R., Lazarus, L. and Kelleher, M. (2016) Long-term follow-up data from pivotal studies of adjuvant trastuzumab in early breast cancer. Targeted Oncology, 11(5), pp. 579-591. (doi: 10.1007/s11523-016-0438-5) (PMID:27181019) (PMCID:PMC5054055)

Bartlett, J. M. S. et al. (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. Journal of the National Cancer Institute, 108(9), djw050. (doi: 10.1093/jnci/djw050) (PMID:27130929) (PMCID:PMC5939629)

Marshall-Mckenna, R. , Morrison, A., Stirling, L., Hutchison, C., Rice, A.M., Hewitt, C., Paul, L., Rodger, M., MacPherson, I. and McCartney, E. (2016) A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Supportive Care in Cancer, 24(4), pp. 1821-1829. (doi: 10.1007/s00520-015-2967-3) (PMID:26446702)

Palmieri, C. et al. (2016) Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget, 7(11), pp. 13209-13220. (doi: 10.18632/oncotarget.4801) (PMID:26334099)

2015

Argilés, G. et al. (2015) Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. European Journal of Cancer, 51(8), pp. 942-949. (doi: 10.1016/j.ejca.2015.02.013) (PMID:25818084)

2014

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi: 10.1016/j.ejca.2014.08.008) (PMID:25441408)

MacPherson, I. R. et al. (2014) CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 127(18), pp. 3893-3901. (doi: 10.1242/jcs.135947) (PMID:25015290)

Macpherson, I.R., Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi: 10.1016/j.clbc.2014.09.009) (PMID:25454689)

Shepherd, S. T.C., Gillen, G., Morrison, P., Forte, C., MacPherson, I. R. , White, J. D. and Mark, P. B. (2014) Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer, 50(5), pp. 944-952. (doi: 10.1016/j.ejca.2013.12.021)

Macagno, J. P., Diaz Vera, J., Yu, Y., MacPherson, I. , Sandilands, E., Palmer, R., Norman, J. C. , Frame, M. and Vidal, M. (2014) FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genetics, 10(3), e1004262. (doi: 10.1371/journal.pgen.1004262)

Shepherd, S. T.C., Macpherson, I. R., White, J. D. and Mark, P. B. (2014) Response to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’. European Journal of Cancer, 25(7), pp. 1497-1503. (doi: 10.1016/j.ejca.2014.04.027)

2013

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi: 10.1016/j.ejca.2012.09.036)

2012

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi: 10.1083/jcb.201203025)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi: 10.1016/j.devcel.2011.11.008)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi: 10.1186/1471-2407-12-536)

2010

MacPherson, I.R.J. , Lindsay, C. and Canney, P. (2010) Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer: Targets and Therapy, 2010(2), pp. 59-70. (doi: 10.2147/BCTT.S11835)

2009

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi: 10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi: 10.2147/BCTT.S6127)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi: 10.2217/FON.09.18)

MacPherson, I.R.J. , Lindsay, C.R. and Reed, N.S. (2009) Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Therapeutics and Clinical Risk Management, 2009(5), pp. 261-270. (doi: 10.2147/TCRM.S3320)

2008

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

2007

MacPherson, I. , Hooper, S., Serrels, A., McGarry, L., Ozanne, B., Harrington, K., Frame, M., Sahai, E. and Brunton, V. (2007) p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene, 26(36), pp. 5214-5228. (doi: 10.1038/sj.onc.1210334)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi: 10.2174/1874079000701010009)

2006

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi: 10.1158/1535-7163.MCT-06-0382)

2004

Brunton, V.G., MacPherson, I.R.J. and Frame, M.C. (2004) Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta: Molecular Cell Research, 1692(02-Mar), pp. 121-144. (doi: 10.1016/j.bbamcr.2004.04.010)

2003

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

Articles

Maldonado, H. et al. (2024) A trafficking regulatory subnetwork governs α V β 6 integrin-HER2 cross-talk to control breast cancer invasion and drug resistance. Science Advances, 10(49), eadk9944. (doi: 10.1126/sciadv.adk9944) (PMID:39630893) (PMCID:39630893)

Hanna, D. et al. (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130(12), pp. 1916-1920. (doi: 10.1038/s41416-024-02685-9) (PMID:38658782) (PMCID:PMC11183215)

Agnew, S., Crawford, M., MacPherson, I. , Shiramizu, V. and Fleming, L. (2024) The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer. Breast, 75, 103731. (doi: 10.1016/j.breast.2024.103731) (PMID:38599048) (PMCID:PMC11017041)

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

Kingston, B. et al. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14(2), pp. 274-289. (doi: 10.1158/2159-8290.CD-22-1387) (PMID:37982575) (PMCID:PMC10850945)

Coakley, M. et al. (2023) Comparison of circulating tumor DNA assays for Molecular Residual Disease detection in early-stage triple negative breast cancer. Clinical Cancer Research, (doi: 10.1158/1078-0432.CCR-23-2326) (Early Online Publication)

Ring, A. et al. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29(23), pp. 4751-4759. (doi: 10.1158/1078-0432.CCR-23-1696) (PMID:37773077) (PMCID:PMC10690092)

Henriksen, P. A. et al. (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial. Circulation, 148(21), pp. 1680-1690. (doi: 10.1161/CIRCULATIONAHA.123.064274) (PMID:37746692) (PMCID:PMC10655910)

Palmieri, C. et al. (2023) A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program. British Journal of Cancer, 129(5), pp. 852-860. (doi: 10.1038/s41416-023-02352-5) (PMID:37468569)

Turner, N. C. et al. (2023) Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer. Annals of Oncology, 34(2), pp. 200-211. (doi: 10.1016/j.annonc.2022.11.005) (PMID:36423745)

Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D. and MacPherson, I. (2022) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a quantitative systematic review. Breast, 64, pp. 63-84. (doi: 10.1016/j.breast.2022.04.010)

Winter, M. et al. (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35, 100442. (doi: 10.1016/j.jbo.2022.100442)

Morrison, A., Marshall-Mckenna, R. , McFadyen, A. K., Hutchison, C., Rice, A.-M., Stirling, L., McIlroy, P. and MacPherson, I. R. (2022) A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer. Scientific Reports, 12, 11575. (doi: 10.1038/s41598-022-13327-6) (PMID:35798751) (PMCID:PMC9262963)

Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)

Coombes, R.C. et al. (2022) Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nature Communications, 13, 3246. (doi: 10.1038/s41467-022-30666-0) (PMID:35688802) (PMCID:PMC9187670)

Razis, E. et al. (2022) Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. ESMO Open, 7(3), 100483. (doi: 10.1016/j.esmoop.2022.100483) (PMID:35576695) (PMCID:PMC9291630)

Malorni, L. et al. (2022) Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 164, pp. 39-51. (doi: 10.1016/j.ejca.2021.12.030) (PMID:35172272)

Rabas, N. et al. (2021) PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. Journal of Cell Biology, 220(12), e202006049. (doi: 10.1083/jcb.202006049) (PMID:34623384) (PMCID:PMC8641410)

Gray, E., Figueroa, J.D., Oikonomidou, O., MacPherson, I. , Urquhart, G., Cameron, D.A. and Hall, P.S. (2021) Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open, 6(6), 100331. (doi: 10.1016/j.esmoop.2021.100331) (PMID:34864502) (PMCID:PMC8649669)

Turner, N. C. et al. (2021) Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study. Clinical Cancer Research, 27(20), pp. 5482-5491. (doi: 10.1158/1078-0432.CCR-21-0310) (PMID:34301749) (PMCID:PMC8530899)

Peddie, N., Agnew, S., Crawford, M., Dixon, D., MacPherson, I. and Fleming, L. (2021) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a qualitative systematic review and thematic synthesis. Breast, 58, pp. 147-159. (doi: 10.1016/j.breast.2021.05.005) (PMID:34049260) (PMCID:PMC8165559)

Palmieri, C. and MacPherson, I. R. (2021) A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients with cancer and liver impairment. ESMO Open, 6(3), 100162. (doi: 10.1016/j.esmoop.2021.100162)

Kingston, B. et al. (2021) Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 12, 2423. (doi: 10.1038/s41467-021-22605-2) (PMID:33893289) (PMCID:PMC8065112)

Macpherson, I. R. , He, Y. and Palmieri, C. (2021) Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305. Breast Cancer Research, 23, 33. (doi: 10.1186/s13058-021-01407-w) (PMID:33736675) (PMCID:PMC7977154)

Earl, H.M. et al. (2021) Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33(1), pp. 15-19. (doi: 10.1016/j.clon.2020.07.006) (PMID:32723485) (PMCID:PMC7382576)

Pascual, J. et al. (2021) Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers. Cancer Discovery, 11(1), pp. 92-107. (doi: 10.1158/2159-8290.CD-20-0553) (PMID:32958578)

Turner, N. C. et al. (2020) Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncology, 21(10), pp. 1296-1308. (doi: 10.1016/S1470-2045(20)30444-7) (PMID:32919527) (PMCID:PMC7599319)

Conefrey, C. et al. (2020) Strategies to improve recruitment to a de-escalation trial: a mixed-methods study of the OPTIMA prelim trial in early breast cancer. Clinical Oncology, 32(6), pp. 382-389. (doi: 10.1016/j.clon.2020.01.029) (PMID:32089356) (PMCID:PMC7246331)

Tzolos, E. et al. (2020) Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy. Clinical Oncology, 32(5), pp. 292-297. (doi: 10.1016/j.clon.2019.11.008) (PMID:31813662) (PMCID:PMC7139216)

Coleman, R. et al. (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials, 21, 89. (doi: 10.1186/s13063-019-3643-6) (PMID:31941523) (PMCID:PMC6961242)

MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)

Banerji, U. et al. (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, 20(8), pp. 1124-1135. (doi: 10.1016/S1470-2045(19)30328-6) (PMID:31257177)

Palmieri, C. and Macpherson, I. (2019) Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution. Lancet Oncology, 20(6), e289. (doi: 10.1016/S1470-2045(19)30296-7) (PMID:31162096)

Copson, E. et al. (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: data from a multi-centre retrospective review. Breast, 42, pp. 133-141. (doi: 10.1016/j.breast.2018.09.003) (PMID:30278369)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, 5069. (doi: 10.1038/s41467-018-07339-y) (PMID:30498210) (PMCID:PMC6265295)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi: 10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Dornier, E. et al. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8, 2255. (doi: 10.1038/s41467-017-02101-2) (PMID:29269878) (PMCID:PMC5740148)

Hall, P. S. et al. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20(10), pp. 1311-1318. (doi: 10.1016/j.jval.2017.04.021) (PMID:29241890)

Cain, H., MacPherson, I.R. , Beresford, M., Pinder, S.E., Pong, J. and Dixon, J.M. (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clinical Oncology, 29(10), pp. 642-652. (doi: 10.1016/j.clon.2017.06.003) (PMID:28669449)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi: 10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I. , Edwards, J. , Zanivan, S. and Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130(4), pp. 697-711. (doi: 10.1242/jcs.190835) (PMID:28062852)

Kristeleit, H., Parton, M., Beresford, M., Macpherson, I. R. , Sharma, R., Lazarus, L. and Kelleher, M. (2016) Long-term follow-up data from pivotal studies of adjuvant trastuzumab in early breast cancer. Targeted Oncology, 11(5), pp. 579-591. (doi: 10.1007/s11523-016-0438-5) (PMID:27181019) (PMCID:PMC5054055)

Bartlett, J. M. S. et al. (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. Journal of the National Cancer Institute, 108(9), djw050. (doi: 10.1093/jnci/djw050) (PMID:27130929) (PMCID:PMC5939629)

Marshall-Mckenna, R. , Morrison, A., Stirling, L., Hutchison, C., Rice, A.M., Hewitt, C., Paul, L., Rodger, M., MacPherson, I. and McCartney, E. (2016) A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Supportive Care in Cancer, 24(4), pp. 1821-1829. (doi: 10.1007/s00520-015-2967-3) (PMID:26446702)

Palmieri, C. et al. (2016) Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget, 7(11), pp. 13209-13220. (doi: 10.18632/oncotarget.4801) (PMID:26334099)

Argilés, G. et al. (2015) Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. European Journal of Cancer, 51(8), pp. 942-949. (doi: 10.1016/j.ejca.2015.02.013) (PMID:25818084)

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi: 10.1016/j.ejca.2014.08.008) (PMID:25441408)

MacPherson, I. R. et al. (2014) CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 127(18), pp. 3893-3901. (doi: 10.1242/jcs.135947) (PMID:25015290)

Macpherson, I.R., Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi: 10.1016/j.clbc.2014.09.009) (PMID:25454689)

Shepherd, S. T.C., Gillen, G., Morrison, P., Forte, C., MacPherson, I. R. , White, J. D. and Mark, P. B. (2014) Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer, 50(5), pp. 944-952. (doi: 10.1016/j.ejca.2013.12.021)

Macagno, J. P., Diaz Vera, J., Yu, Y., MacPherson, I. , Sandilands, E., Palmer, R., Norman, J. C. , Frame, M. and Vidal, M. (2014) FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genetics, 10(3), e1004262. (doi: 10.1371/journal.pgen.1004262)

Shepherd, S. T.C., Macpherson, I. R., White, J. D. and Mark, P. B. (2014) Response to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’. European Journal of Cancer, 25(7), pp. 1497-1503. (doi: 10.1016/j.ejca.2014.04.027)

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi: 10.1016/j.ejca.2012.09.036)

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi: 10.1083/jcb.201203025)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi: 10.1016/j.devcel.2011.11.008)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi: 10.1186/1471-2407-12-536)

MacPherson, I.R.J. , Lindsay, C. and Canney, P. (2010) Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer: Targets and Therapy, 2010(2), pp. 59-70. (doi: 10.2147/BCTT.S11835)

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi: 10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi: 10.2147/BCTT.S6127)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi: 10.2217/FON.09.18)

MacPherson, I.R.J. , Lindsay, C.R. and Reed, N.S. (2009) Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Therapeutics and Clinical Risk Management, 2009(5), pp. 261-270. (doi: 10.2147/TCRM.S3320)

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

MacPherson, I. , Hooper, S., Serrels, A., McGarry, L., Ozanne, B., Harrington, K., Frame, M., Sahai, E. and Brunton, V. (2007) p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene, 26(36), pp. 5214-5228. (doi: 10.1038/sj.onc.1210334)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi: 10.2174/1874079000701010009)

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi: 10.1158/1535-7163.MCT-06-0382)

Brunton, V.G., MacPherson, I.R.J. and Frame, M.C. (2004) Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta: Molecular Cell Research, 1692(02-Mar), pp. 121-144. (doi: 10.1016/j.bbamcr.2004.04.010)

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

Conference or Workshop Item

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) The NTOX-G12- A New Clinical Assessment Tool for Nail Problems as a Result of Taxane Chemotherapy Regimens. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) Taxane Chemotherapy and Nail Toxicity in Women with Breast Cancer: An Evaluation of Interventions. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

2024

Maldonado, H. et al. (2024) A trafficking regulatory subnetwork governs α V β 6 integrin-HER2 cross-talk to control breast cancer invasion and drug resistance. Science Advances, 10(49), eadk9944. (doi: 10.1126/sciadv.adk9944) (PMID:39630893) (PMCID:39630893)

Hanna, D. et al. (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130(12), pp. 1916-1920. (doi: 10.1038/s41416-024-02685-9) (PMID:38658782) (PMCID:PMC11183215)

Agnew, S., Crawford, M., MacPherson, I. , Shiramizu, V. and Fleming, L. (2024) The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer. Breast, 75, 103731. (doi: 10.1016/j.breast.2024.103731) (PMID:38599048) (PMCID:PMC11017041)

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

Kingston, B. et al. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14(2), pp. 274-289. (doi: 10.1158/2159-8290.CD-22-1387) (PMID:37982575) (PMCID:PMC10850945)

2023

Coakley, M. et al. (2023) Comparison of circulating tumor DNA assays for Molecular Residual Disease detection in early-stage triple negative breast cancer. Clinical Cancer Research, (doi: 10.1158/1078-0432.CCR-23-2326) (Early Online Publication)

Ring, A. et al. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29(23), pp. 4751-4759. (doi: 10.1158/1078-0432.CCR-23-1696) (PMID:37773077) (PMCID:PMC10690092)

Henriksen, P. A. et al. (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial. Circulation, 148(21), pp. 1680-1690. (doi: 10.1161/CIRCULATIONAHA.123.064274) (PMID:37746692) (PMCID:PMC10655910)

Palmieri, C. et al. (2023) A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program. British Journal of Cancer, 129(5), pp. 852-860. (doi: 10.1038/s41416-023-02352-5) (PMID:37468569)

Turner, N. C. et al. (2023) Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer. Annals of Oncology, 34(2), pp. 200-211. (doi: 10.1016/j.annonc.2022.11.005) (PMID:36423745)

2022

Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D. and MacPherson, I. (2022) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a quantitative systematic review. Breast, 64, pp. 63-84. (doi: 10.1016/j.breast.2022.04.010)

Winter, M. et al. (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35, 100442. (doi: 10.1016/j.jbo.2022.100442)

Morrison, A., Marshall-Mckenna, R. , McFadyen, A. K., Hutchison, C., Rice, A.-M., Stirling, L., McIlroy, P. and MacPherson, I. R. (2022) A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer. Scientific Reports, 12, 11575. (doi: 10.1038/s41598-022-13327-6) (PMID:35798751) (PMCID:PMC9262963)

Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)

Coombes, R.C. et al. (2022) Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nature Communications, 13, 3246. (doi: 10.1038/s41467-022-30666-0) (PMID:35688802) (PMCID:PMC9187670)

Razis, E. et al. (2022) Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. ESMO Open, 7(3), 100483. (doi: 10.1016/j.esmoop.2022.100483) (PMID:35576695) (PMCID:PMC9291630)

Malorni, L. et al. (2022) Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 164, pp. 39-51. (doi: 10.1016/j.ejca.2021.12.030) (PMID:35172272)

2021

Rabas, N. et al. (2021) PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. Journal of Cell Biology, 220(12), e202006049. (doi: 10.1083/jcb.202006049) (PMID:34623384) (PMCID:PMC8641410)

Gray, E., Figueroa, J.D., Oikonomidou, O., MacPherson, I. , Urquhart, G., Cameron, D.A. and Hall, P.S. (2021) Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open, 6(6), 100331. (doi: 10.1016/j.esmoop.2021.100331) (PMID:34864502) (PMCID:PMC8649669)

Turner, N. C. et al. (2021) Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study. Clinical Cancer Research, 27(20), pp. 5482-5491. (doi: 10.1158/1078-0432.CCR-21-0310) (PMID:34301749) (PMCID:PMC8530899)

Peddie, N., Agnew, S., Crawford, M., Dixon, D., MacPherson, I. and Fleming, L. (2021) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a qualitative systematic review and thematic synthesis. Breast, 58, pp. 147-159. (doi: 10.1016/j.breast.2021.05.005) (PMID:34049260) (PMCID:PMC8165559)

Palmieri, C. and MacPherson, I. R. (2021) A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients with cancer and liver impairment. ESMO Open, 6(3), 100162. (doi: 10.1016/j.esmoop.2021.100162)

Kingston, B. et al. (2021) Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 12, 2423. (doi: 10.1038/s41467-021-22605-2) (PMID:33893289) (PMCID:PMC8065112)

Macpherson, I. R. , He, Y. and Palmieri, C. (2021) Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305. Breast Cancer Research, 23, 33. (doi: 10.1186/s13058-021-01407-w) (PMID:33736675) (PMCID:PMC7977154)

Earl, H.M. et al. (2021) Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33(1), pp. 15-19. (doi: 10.1016/j.clon.2020.07.006) (PMID:32723485) (PMCID:PMC7382576)

Pascual, J. et al. (2021) Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers. Cancer Discovery, 11(1), pp. 92-107. (doi: 10.1158/2159-8290.CD-20-0553) (PMID:32958578)

2020

Turner, N. C. et al. (2020) Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncology, 21(10), pp. 1296-1308. (doi: 10.1016/S1470-2045(20)30444-7) (PMID:32919527) (PMCID:PMC7599319)

Conefrey, C. et al. (2020) Strategies to improve recruitment to a de-escalation trial: a mixed-methods study of the OPTIMA prelim trial in early breast cancer. Clinical Oncology, 32(6), pp. 382-389. (doi: 10.1016/j.clon.2020.01.029) (PMID:32089356) (PMCID:PMC7246331)

Tzolos, E. et al. (2020) Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy. Clinical Oncology, 32(5), pp. 292-297. (doi: 10.1016/j.clon.2019.11.008) (PMID:31813662) (PMCID:PMC7139216)

Coleman, R. et al. (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials, 21, 89. (doi: 10.1186/s13063-019-3643-6) (PMID:31941523) (PMCID:PMC6961242)

2019

MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)

Banerji, U. et al. (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, 20(8), pp. 1124-1135. (doi: 10.1016/S1470-2045(19)30328-6) (PMID:31257177)

Palmieri, C. and Macpherson, I. (2019) Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution. Lancet Oncology, 20(6), e289. (doi: 10.1016/S1470-2045(19)30296-7) (PMID:31162096)

2018

Copson, E. et al. (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: data from a multi-centre retrospective review. Breast, 42, pp. 133-141. (doi: 10.1016/j.breast.2018.09.003) (PMID:30278369)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, 5069. (doi: 10.1038/s41467-018-07339-y) (PMID:30498210) (PMCID:PMC6265295)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi: 10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) The NTOX-G12- A New Clinical Assessment Tool for Nail Problems as a Result of Taxane Chemotherapy Regimens. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) Taxane Chemotherapy and Nail Toxicity in Women with Breast Cancer: An Evaluation of Interventions. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

2017

Dornier, E. et al. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8, 2255. (doi: 10.1038/s41467-017-02101-2) (PMID:29269878) (PMCID:PMC5740148)

Hall, P. S. et al. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20(10), pp. 1311-1318. (doi: 10.1016/j.jval.2017.04.021) (PMID:29241890)

Cain, H., MacPherson, I.R. , Beresford, M., Pinder, S.E., Pong, J. and Dixon, J.M. (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clinical Oncology, 29(10), pp. 642-652. (doi: 10.1016/j.clon.2017.06.003) (PMID:28669449)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi: 10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I. , Edwards, J. , Zanivan, S. and Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130(4), pp. 697-711. (doi: 10.1242/jcs.190835) (PMID:28062852)

2016

Kristeleit, H., Parton, M., Beresford, M., Macpherson, I. R. , Sharma, R., Lazarus, L. and Kelleher, M. (2016) Long-term follow-up data from pivotal studies of adjuvant trastuzumab in early breast cancer. Targeted Oncology, 11(5), pp. 579-591. (doi: 10.1007/s11523-016-0438-5) (PMID:27181019) (PMCID:PMC5054055)

Bartlett, J. M. S. et al. (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. Journal of the National Cancer Institute, 108(9), djw050. (doi: 10.1093/jnci/djw050) (PMID:27130929) (PMCID:PMC5939629)

Marshall-Mckenna, R. , Morrison, A., Stirling, L., Hutchison, C., Rice, A.M., Hewitt, C., Paul, L., Rodger, M., MacPherson, I. and McCartney, E. (2016) A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Supportive Care in Cancer, 24(4), pp. 1821-1829. (doi: 10.1007/s00520-015-2967-3) (PMID:26446702)

Palmieri, C. et al. (2016) Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget, 7(11), pp. 13209-13220. (doi: 10.18632/oncotarget.4801) (PMID:26334099)

2015

Argilés, G. et al. (2015) Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. European Journal of Cancer, 51(8), pp. 942-949. (doi: 10.1016/j.ejca.2015.02.013) (PMID:25818084)

2014

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi: 10.1016/j.ejca.2014.08.008) (PMID:25441408)

MacPherson, I. R. et al. (2014) CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 127(18), pp. 3893-3901. (doi: 10.1242/jcs.135947) (PMID:25015290)

Macpherson, I.R., Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi: 10.1016/j.clbc.2014.09.009) (PMID:25454689)

Shepherd, S. T.C., Gillen, G., Morrison, P., Forte, C., MacPherson, I. R. , White, J. D. and Mark, P. B. (2014) Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer, 50(5), pp. 944-952. (doi: 10.1016/j.ejca.2013.12.021)

Macagno, J. P., Diaz Vera, J., Yu, Y., MacPherson, I. , Sandilands, E., Palmer, R., Norman, J. C. , Frame, M. and Vidal, M. (2014) FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genetics, 10(3), e1004262. (doi: 10.1371/journal.pgen.1004262)

Shepherd, S. T.C., Macpherson, I. R., White, J. D. and Mark, P. B. (2014) Response to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’. European Journal of Cancer, 25(7), pp. 1497-1503. (doi: 10.1016/j.ejca.2014.04.027)

2013

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi: 10.1016/j.ejca.2012.09.036)

2012

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi: 10.1083/jcb.201203025)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi: 10.1016/j.devcel.2011.11.008)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi: 10.1186/1471-2407-12-536)

2010

MacPherson, I.R.J. , Lindsay, C. and Canney, P. (2010) Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer: Targets and Therapy, 2010(2), pp. 59-70. (doi: 10.2147/BCTT.S11835)

2009

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi: 10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi: 10.2147/BCTT.S6127)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi: 10.2217/FON.09.18)

MacPherson, I.R.J. , Lindsay, C.R. and Reed, N.S. (2009) Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Therapeutics and Clinical Risk Management, 2009(5), pp. 261-270. (doi: 10.2147/TCRM.S3320)

2008

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

2007

MacPherson, I. , Hooper, S., Serrels, A., McGarry, L., Ozanne, B., Harrington, K., Frame, M., Sahai, E. and Brunton, V. (2007) p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene, 26(36), pp. 5214-5228. (doi: 10.1038/sj.onc.1210334)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi: 10.2174/1874079000701010009)

2006

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi: 10.1158/1535-7163.MCT-06-0382)

2004

Brunton, V.G., MacPherson, I.R.J. and Frame, M.C. (2004) Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta: Molecular Cell Research, 1692(02-Mar), pp. 121-144. (doi: 10.1016/j.bbamcr.2004.04.010)

2003

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

Articles

Maldonado, H. et al. (2024) A trafficking regulatory subnetwork governs α V β 6 integrin-HER2 cross-talk to control breast cancer invasion and drug resistance. Science Advances, 10(49), eadk9944. (doi: 10.1126/sciadv.adk9944) (PMID:39630893) (PMCID:39630893)

Hanna, D. et al. (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130(12), pp. 1916-1920. (doi: 10.1038/s41416-024-02685-9) (PMID:38658782) (PMCID:PMC11183215)

Agnew, S., Crawford, M., MacPherson, I. , Shiramizu, V. and Fleming, L. (2024) The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer. Breast, 75, 103731. (doi: 10.1016/j.breast.2024.103731) (PMID:38599048) (PMCID:PMC11017041)

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

Kingston, B. et al. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14(2), pp. 274-289. (doi: 10.1158/2159-8290.CD-22-1387) (PMID:37982575) (PMCID:PMC10850945)

Coakley, M. et al. (2023) Comparison of circulating tumor DNA assays for Molecular Residual Disease detection in early-stage triple negative breast cancer. Clinical Cancer Research, (doi: 10.1158/1078-0432.CCR-23-2326) (Early Online Publication)

Ring, A. et al. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29(23), pp. 4751-4759. (doi: 10.1158/1078-0432.CCR-23-1696) (PMID:37773077) (PMCID:PMC10690092)

Henriksen, P. A. et al. (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial. Circulation, 148(21), pp. 1680-1690. (doi: 10.1161/CIRCULATIONAHA.123.064274) (PMID:37746692) (PMCID:PMC10655910)

Palmieri, C. et al. (2023) A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program. British Journal of Cancer, 129(5), pp. 852-860. (doi: 10.1038/s41416-023-02352-5) (PMID:37468569)

Turner, N. C. et al. (2023) Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer. Annals of Oncology, 34(2), pp. 200-211. (doi: 10.1016/j.annonc.2022.11.005) (PMID:36423745)

Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D. and MacPherson, I. (2022) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a quantitative systematic review. Breast, 64, pp. 63-84. (doi: 10.1016/j.breast.2022.04.010)

Winter, M. et al. (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35, 100442. (doi: 10.1016/j.jbo.2022.100442)

Morrison, A., Marshall-Mckenna, R. , McFadyen, A. K., Hutchison, C., Rice, A.-M., Stirling, L., McIlroy, P. and MacPherson, I. R. (2022) A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer. Scientific Reports, 12, 11575. (doi: 10.1038/s41598-022-13327-6) (PMID:35798751) (PMCID:PMC9262963)

Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)

Coombes, R.C. et al. (2022) Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nature Communications, 13, 3246. (doi: 10.1038/s41467-022-30666-0) (PMID:35688802) (PMCID:PMC9187670)

Razis, E. et al. (2022) Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. ESMO Open, 7(3), 100483. (doi: 10.1016/j.esmoop.2022.100483) (PMID:35576695) (PMCID:PMC9291630)

Malorni, L. et al. (2022) Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 164, pp. 39-51. (doi: 10.1016/j.ejca.2021.12.030) (PMID:35172272)

Rabas, N. et al. (2021) PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. Journal of Cell Biology, 220(12), e202006049. (doi: 10.1083/jcb.202006049) (PMID:34623384) (PMCID:PMC8641410)

Gray, E., Figueroa, J.D., Oikonomidou, O., MacPherson, I. , Urquhart, G., Cameron, D.A. and Hall, P.S. (2021) Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open, 6(6), 100331. (doi: 10.1016/j.esmoop.2021.100331) (PMID:34864502) (PMCID:PMC8649669)

Turner, N. C. et al. (2021) Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study. Clinical Cancer Research, 27(20), pp. 5482-5491. (doi: 10.1158/1078-0432.CCR-21-0310) (PMID:34301749) (PMCID:PMC8530899)

Peddie, N., Agnew, S., Crawford, M., Dixon, D., MacPherson, I. and Fleming, L. (2021) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a qualitative systematic review and thematic synthesis. Breast, 58, pp. 147-159. (doi: 10.1016/j.breast.2021.05.005) (PMID:34049260) (PMCID:PMC8165559)

Palmieri, C. and MacPherson, I. R. (2021) A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients with cancer and liver impairment. ESMO Open, 6(3), 100162. (doi: 10.1016/j.esmoop.2021.100162)

Kingston, B. et al. (2021) Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 12, 2423. (doi: 10.1038/s41467-021-22605-2) (PMID:33893289) (PMCID:PMC8065112)

Macpherson, I. R. , He, Y. and Palmieri, C. (2021) Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305. Breast Cancer Research, 23, 33. (doi: 10.1186/s13058-021-01407-w) (PMID:33736675) (PMCID:PMC7977154)

Earl, H.M. et al. (2021) Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33(1), pp. 15-19. (doi: 10.1016/j.clon.2020.07.006) (PMID:32723485) (PMCID:PMC7382576)

Pascual, J. et al. (2021) Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers. Cancer Discovery, 11(1), pp. 92-107. (doi: 10.1158/2159-8290.CD-20-0553) (PMID:32958578)

Turner, N. C. et al. (2020) Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncology, 21(10), pp. 1296-1308. (doi: 10.1016/S1470-2045(20)30444-7) (PMID:32919527) (PMCID:PMC7599319)

Conefrey, C. et al. (2020) Strategies to improve recruitment to a de-escalation trial: a mixed-methods study of the OPTIMA prelim trial in early breast cancer. Clinical Oncology, 32(6), pp. 382-389. (doi: 10.1016/j.clon.2020.01.029) (PMID:32089356) (PMCID:PMC7246331)

Tzolos, E. et al. (2020) Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy. Clinical Oncology, 32(5), pp. 292-297. (doi: 10.1016/j.clon.2019.11.008) (PMID:31813662) (PMCID:PMC7139216)

Coleman, R. et al. (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials, 21, 89. (doi: 10.1186/s13063-019-3643-6) (PMID:31941523) (PMCID:PMC6961242)

MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)

Banerji, U. et al. (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, 20(8), pp. 1124-1135. (doi: 10.1016/S1470-2045(19)30328-6) (PMID:31257177)

Palmieri, C. and Macpherson, I. (2019) Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution. Lancet Oncology, 20(6), e289. (doi: 10.1016/S1470-2045(19)30296-7) (PMID:31162096)

Copson, E. et al. (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: data from a multi-centre retrospective review. Breast, 42, pp. 133-141. (doi: 10.1016/j.breast.2018.09.003) (PMID:30278369)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, 5069. (doi: 10.1038/s41467-018-07339-y) (PMID:30498210) (PMCID:PMC6265295)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi: 10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Dornier, E. et al. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8, 2255. (doi: 10.1038/s41467-017-02101-2) (PMID:29269878) (PMCID:PMC5740148)

Hall, P. S. et al. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20(10), pp. 1311-1318. (doi: 10.1016/j.jval.2017.04.021) (PMID:29241890)

Cain, H., MacPherson, I.R. , Beresford, M., Pinder, S.E., Pong, J. and Dixon, J.M. (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clinical Oncology, 29(10), pp. 642-652. (doi: 10.1016/j.clon.2017.06.003) (PMID:28669449)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi: 10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I. , Edwards, J. , Zanivan, S. and Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130(4), pp. 697-711. (doi: 10.1242/jcs.190835) (PMID:28062852)

Kristeleit, H., Parton, M., Beresford, M., Macpherson, I. R. , Sharma, R., Lazarus, L. and Kelleher, M. (2016) Long-term follow-up data from pivotal studies of adjuvant trastuzumab in early breast cancer. Targeted Oncology, 11(5), pp. 579-591. (doi: 10.1007/s11523-016-0438-5) (PMID:27181019) (PMCID:PMC5054055)

Bartlett, J. M. S. et al. (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. Journal of the National Cancer Institute, 108(9), djw050. (doi: 10.1093/jnci/djw050) (PMID:27130929) (PMCID:PMC5939629)

Marshall-Mckenna, R. , Morrison, A., Stirling, L., Hutchison, C., Rice, A.M., Hewitt, C., Paul, L., Rodger, M., MacPherson, I. and McCartney, E. (2016) A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Supportive Care in Cancer, 24(4), pp. 1821-1829. (doi: 10.1007/s00520-015-2967-3) (PMID:26446702)

Palmieri, C. et al. (2016) Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget, 7(11), pp. 13209-13220. (doi: 10.18632/oncotarget.4801) (PMID:26334099)

Argilés, G. et al. (2015) Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. European Journal of Cancer, 51(8), pp. 942-949. (doi: 10.1016/j.ejca.2015.02.013) (PMID:25818084)

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi: 10.1016/j.ejca.2014.08.008) (PMID:25441408)

MacPherson, I. R. et al. (2014) CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 127(18), pp. 3893-3901. (doi: 10.1242/jcs.135947) (PMID:25015290)

Macpherson, I.R., Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi: 10.1016/j.clbc.2014.09.009) (PMID:25454689)

Shepherd, S. T.C., Gillen, G., Morrison, P., Forte, C., MacPherson, I. R. , White, J. D. and Mark, P. B. (2014) Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer, 50(5), pp. 944-952. (doi: 10.1016/j.ejca.2013.12.021)

Macagno, J. P., Diaz Vera, J., Yu, Y., MacPherson, I. , Sandilands, E., Palmer, R., Norman, J. C. , Frame, M. and Vidal, M. (2014) FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genetics, 10(3), e1004262. (doi: 10.1371/journal.pgen.1004262)

Shepherd, S. T.C., Macpherson, I. R., White, J. D. and Mark, P. B. (2014) Response to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’. European Journal of Cancer, 25(7), pp. 1497-1503. (doi: 10.1016/j.ejca.2014.04.027)

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi: 10.1016/j.ejca.2012.09.036)

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi: 10.1083/jcb.201203025)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi: 10.1016/j.devcel.2011.11.008)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi: 10.1186/1471-2407-12-536)

MacPherson, I.R.J. , Lindsay, C. and Canney, P. (2010) Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer: Targets and Therapy, 2010(2), pp. 59-70. (doi: 10.2147/BCTT.S11835)

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi: 10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi: 10.2147/BCTT.S6127)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi: 10.2217/FON.09.18)

MacPherson, I.R.J. , Lindsay, C.R. and Reed, N.S. (2009) Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Therapeutics and Clinical Risk Management, 2009(5), pp. 261-270. (doi: 10.2147/TCRM.S3320)

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

MacPherson, I. , Hooper, S., Serrels, A., McGarry, L., Ozanne, B., Harrington, K., Frame, M., Sahai, E. and Brunton, V. (2007) p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene, 26(36), pp. 5214-5228. (doi: 10.1038/sj.onc.1210334)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi: 10.2174/1874079000701010009)

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi: 10.1158/1535-7163.MCT-06-0382)

Brunton, V.G., MacPherson, I.R.J. and Frame, M.C. (2004) Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta: Molecular Cell Research, 1692(02-Mar), pp. 121-144. (doi: 10.1016/j.bbamcr.2004.04.010)

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

Conference or Workshop Item

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) The NTOX-G12- A New Clinical Assessment Tool for Nail Problems as a Result of Taxane Chemotherapy Regimens. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) Taxane Chemotherapy and Nail Toxicity in Women with Breast Cancer: An Evaluation of Interventions. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)